Skip to Content
DAEWOONG PHARMACEUTICAL CO.LTD.
About Daewoong
About Daewoong
Global Network
Company Culture
History
Ethics
Contact Us
R&D
R&D Centers
R&D Projects
Achievements
Research Result
Platform Technology
Manufacturing Capabilities
Plants
Smart Factory
FDF CDMO
Product
Biologics
Chemicals
CTD List
Newsroom
Press Release
PR Videos
Investors
Overview
Corporate Governance
Annual Reports
Stock Info
IR
Careers
EN
KR
EN
View all menu
About Daewoong
About Daewoong
Our Purpose
CEO Message
Affiliates
Global Network
Company Culture
History
Ethics
Compliance Program
CEO Message
CP Rating
CP Activities
Contact Us
R&D
R&D Centers
R&D Projects
Achievements
Research Result
Platform Technology
Manufacturing
Capabilities
Plants
Smart Factory
FDF CDMO
Product
Biologics
Chemicals
CTD List
Newsroom
Press Release
PR Videos
Investors
Overview
Corporate Governance
Overview
Board of Directors
Stockholder Info
Stockholder's meeting
Annual Reports
Balance Sheet
Income Statement
Credit Rating
Stock Info
Stock Info
Stock Status
IR
Events & Presentations
Earnings announcement
FAQ
Careers
Daewoong
Global Healthcare Group
The Best Partner for You
Press Release
Daewoong Pharmaceutical’s press release
NEW
1
Daewoong Pharmaceutical submits a new drug application (NDA) for Enavogliflozin in Mexico
2024-04
15
NEW
2
Daewoong Pharmaceutical's AI System Processes 800 Million Compounds, Boosting Obesity and Cancer Research
2024-02
21
NEW
3
Daewoong Pharmaceutical Announces 2023 Financial Results
2024-02
05
Daewoong Pharmaceutical submits a new drug application (NDA) for Enavogliflozin in Mexico
2024-04-15
Daewoong Pharmaceutical's AI System Processes 800 Million Compounds, Boosting Obesity and Cancer Research
2024-02-21
Daewoong Pharmaceutical Announces 2023 Financial Results
2024-02-05
Daewoong Pharmaceutical's Bersiporocin Receives ‘Orphan Drug Designation’ in Europe to Treat Idiopathic Pulmonary Fibrosis
2024-01-29
Daewoong Pharmaceutical and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S.
2023-12-11
Daewoong Pharmaceutical Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin
2023-12-06
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA
2023-11-28
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Microneedle Technology for Sustained Weekly Efficacy
2023-11-07
Daewoong Pharmaceutical Reports Third Quarter 2023 Financial Results
2023-11-06
1
2
3
4
5
6
7
8
9
10
다음 페이지
Search
search word
Delete
Search